Brief: Jw (Cayman) Therapeutics Says Strategic Partnership With 2Seventy Bio, Inc
Jan 2 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* STRATEGIC PARTNERSHIP WITH 2SEVENTY BIO, INC
* ENTERED INTO AN EXCLUSIVE COLLABORATION AGREEMENT WITH
2SEVENTY
BIO ON JAN 1
* AGREEMENT FOR CO-DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTOR
T CELL
THERAPY PRODUCT FOR AUTOIMMUNE DISEASES IN GREATER CHINA
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License